RedNASHEmpagliflozin for Non-Alcoholic Steatohepatitis

This clinical trial aims to determine whether empagliflozin, a medication typically used to treat diabetes, can help improve liver health in adults with non-alcoholic steatohepatitis (NASH). NASH is a liver condition that can lead to serious liver damage, and currently, treatment options are limited. By exploring the effects of empagliflozin over a 48-week period, this study hopes to find a new and effective way to manage this condition. It is important because finding a successful treatment could significantly improve the quality of life for those affected by NASH. Participants in the study will take the drug empagliflozin daily for one year. They will attend regular clinic visits at specific intervals—weeks 1, 2, 4, 12, 24, 36, and 48—to monitor their health and the medication's effects. These visits include a variety of assessments such as blood tests, measurements of liver stiffness using non-invasive methods, and checks on their overall physical health. The study evaluates changes in the liver's condition and overall health indicators to determine if empagliflozin is beneficial in treating NASH. While potential benefits include improved liver health, the study also carefully monitors for any adverse effects throughout the treatment period.